Editorial

Accepted on 20 Sep 2024

Editorial: Editors' Showcase: Red Cells, Iron and Erythropoiesis

Anna Rita Migliaccio

Frontiers in Hematology

doi 10.3389/frhem.2024.1457513

Original Research

Published on 11 Sep 2024

REAL-LIFE EXPERIENCE WITH FIRST-LINE TREATMENT WITH DARATUMUMAB, BORTEZOMIB, MELPHALAN, AND PREDNISONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA INELIGIBLE FOR AUTOLOGOUS STEM-CELL TRANSPLANTATION

Amalia Domingo-González
Rafael Alonso Fernández
Ana Jiménez
Teresa De Soto Álvarez
Ana Lerma
Virginia Pradillo Fernández
Gonzalo Benzo Callejo
Jose Sánchez-Pina
Elena Landete
Alberto Velasco

Frontiers in Hematology

doi 10.3389/frhem.2024.1438233

228 views

Review

Accepted on 09 Sep 2024

Clonal Evolution: A landmark of MPN evolution

Nabih Maslah
Stephane Giraudier
Bruno Cassinat
Jean-Jacques Kiladjian

Frontiers in Hematology

doi 10.3389/frhem.2024.1473920

Review

Accepted on 05 Sep 2024

Dissecting dormancy and quiescence in hematopoietic stem cells

Liliia Ibneeva
Tatyana Grinenko

Frontiers in Hematology

doi 10.3389/frhem.2024.1401713

Perspective

Accepted on 05 Sep 2024

The CHIP Clinic as The Catalyst of Preventive Medicine

Hans Carl Hasselbalch
Vibe Skov
Lasse Kjaer
Trine Alma Knudsen
Christina Schjellerup Eickhardt-Dalbøge
Christina Ellervik
Sabrina Cordua
Anders Lindholm Sørensen
Sarah Friis Christensen
Marie Hvelplund Kristiansen

Frontiers in Hematology

doi 10.3389/frhem.2024.1459154

Review

Accepted on 30 Aug 2024

Recent Advancements in Gene Therapy for Sickle Cell Disease and β-Thalassemia

Lushen Li
Pankaj Kumar Mandal

Frontiers in Hematology

doi 10.3389/frhem.2024.1468952

Editorial

Published on 29 Aug 2024

Rising Stars in Hematopoiesis and Stem Cells 2023

Marcus O. Muench
Kristbjorn Orri Gudmundsson

Frontiers in Hematology

doi 10.3389/frhem.2024.1477997

195 views

Perspective

Published on 27 Aug 2024

Sickle Cell Disease: A Comparative Perspective on Global and National Initiatives

Alok Kumar
Sudip Bhattacharya

Frontiers in Hematology

doi 10.3389/frhem.2024.1457158

236 views

Study Protocol

Accepted on 20 Aug 2024

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)

Theo Leitner
Evgenii Shumilov
Christina Schwitlick
Raphael Koch
Franziska Hamm
Marion Högner
Florian Bassermann
Katja Weisel
Hermann Einsele
Leo Rasche

Frontiers in Hematology

doi 10.3389/frhem.2024.1436845

Editorial

Published on 14 Aug 2024

Glycobiology in Hematology, a Promising Avenue for Cancer Diagnostics and Therapeutics

Tao Zhang
Valerie R. Wiersma

Frontiers in Hematology

doi 10.3389/frhem.2024.1465473

426 views

Review

Published on 09 Aug 2024

The Nexus Between Helicobacter Pylori Infection and Anemia

Sankeerth Kumar Motupalli
Terry L Ororzi

Frontiers in Hematology

doi 10.3389/frhem.2024.1423494

371 views

Review

Published on 06 Aug 2024

Are we ready to integrate 3D culture systems in acute myeloid leukemia and bone marrow microenvironment research?

Azmeer Sharipol
Benjamin J. Frisch

Frontiers in Hematology

doi 10.3389/frhem.2024.1407698

546 views

Community Case Study

Published on 25 Jul 2024

Effectiveness of biosimilar pegfilgrastim in patients with Lymphoma after highdose chemotherapy and autologous stem cell transplantation: a real-life study

Barbara Loteta
Annalisa Pitino
Martina Pitea
Caterina Alati
Giovanni Tripepi
Maria Caterina Mico'
Maria Pellicano'
Francesca Cogliandro
Gaetana Porto
Giorgia Policastro

Frontiers in Hematology

doi 10.3389/frhem.2024.1441070

403 views

Mini Review

Published on 22 Jul 2024

Targeting the bone marrow niche, moving towards leukemia eradication

Carla Semedo
Raquel Caroço
António Medina Almeida
Bruno António Cardoso

Frontiers in Hematology

doi 10.3389/frhem.2024.1429916

482 views

Original Research

Published on 15 Jul 2024

Real-World Analysis of the Underdiagnosis, Clinical Outcomes and Associated Burden of Hematopoietic Stem Cell Transplantationassociated Thrombotic Microangiopathy (HSCT-TMA) in the United States

Yan Wang
Andrew Rava
Marlene Smurzynski
Bonny Shah
Anusorn Thanataveerat
Imad Al-Dakkak
Moh-Lim Ong
Christopher C Dvorak
Vincent T. Ho

Frontiers in Hematology

doi 10.3389/frhem.2024.1405311

774 views

Review

Published on 12 Jul 2024

Clonal Cytopenia of Undetermined Significance: Definitions, Risk and Therapeutic Targets

Cristian C Taborda
Amer Zeidan
Lourdes Mendez

Frontiers in Hematology

doi 10.3389/frhem.2024.1419323

725 views

Navigation group

Volumes

Volume 3 - 2024

Editorial: Editors' Showcase: Red Cells, Iron and Erythropoiesis

REAL-LIFE EXPERIENCE WITH FIRST-LINE TREATMENT WITH DARATUMUMAB, BORTEZOMIB, MELPHALAN, AND PREDNISONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA INELIGIBLE FOR AUTOLOGOUS STEM-CELL TRANSPLANTATION

Clonal Evolution: A landmark of MPN evolution

Dissecting dormancy and quiescence in hematopoietic stem cells

The CHIP Clinic as The Catalyst of Preventive Medicine

Recent Advancements in Gene Therapy for Sickle Cell Disease and β-Thalassemia

Rising Stars in Hematopoiesis and Stem Cells 2023

Sickle Cell Disease: A Comparative Perspective on Global and National Initiatives

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)

Glycobiology in Hematology, a Promising Avenue for Cancer Diagnostics and Therapeutics

The Nexus Between Helicobacter Pylori Infection and Anemia

Are we ready to integrate 3D culture systems in acute myeloid leukemia and bone marrow microenvironment research?

Effectiveness of biosimilar pegfilgrastim in patients with Lymphoma after highdose chemotherapy and autologous stem cell transplantation: a real-life study

Targeting the bone marrow niche, moving towards leukemia eradication

Real-World Analysis of the Underdiagnosis, Clinical Outcomes and Associated Burden of Hematopoietic Stem Cell Transplantationassociated Thrombotic Microangiopathy (HSCT-TMA) in the United States

Clonal Cytopenia of Undetermined Significance: Definitions, Risk and Therapeutic Targets